-
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO, Anderson JM, Anwandter G, Nekrasova K, Nicolaides KH.
Prenat Diagn 2008;28:1209-13. -
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.
Hum Reprod 2008;23:1968-75. -
Aberrant right subclavian artery at 11 + 0 to 13 + 6 weeks of gestation in chromosomally normal and abnormal fetuses.
Borenstein M, Cavoretto P, Allan L, Huggon I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:20-4. -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4. -
Sonographic screening for trisomy 13 at 11 to 13(+6) weeks of gestation.
Papageorghiou AT, Avgidou K, Spencer K, Nix B, Nicolaides KH.
Am J Obstet Gynecol 2006;194:397-401. -
The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues.
Wilting J, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Borges J, Stark GB, Alitalo K, Tomarev SI, Niemeyer C, Rossler J.
FASEB J 2002;16:1271-3. -
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2002;22:877-9. -
Congenital nephrotic syndrome presenting with increased nuchal translucency in the first trimester.
Souka AP, Skentou H, Geerts L, Bower S, Nicolaides KH.
Prenat Diagn 2002;22:93-5. -
Congenital lymphedema presenting with increased nuchal translucency at 13 weeks of gestation.
Souka AP, Krampl E, Geerts L, Nicolaides KH.
Prenat Diagn 2002;22:91-2. -
Hypophosphatasia associated with increased nuchal translucency: a report of two affected pregnancies.
Souka AP, Raymond FL, Mornet E, Geerts L, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;20:294-5. -
Blackfan-Diamond anemia and dyserythropoietic anemia presenting with increased nuchal translucency at 12 weeks of gestation.
Souka AP, Bower S, Geerts L, Huggon I, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;20:197-9. -
Second-trimester uterine artery Doppler screening in unselected populations: a review.
Papageorghiou AT, Yu CK, Cicero S, Bower S, Nicolaides KH.
J Matern Fetal Neonatal Med 2002;12:78-88. -
Increased fetal nuchal translucency at 11-14 weeks.
Nicolaides KH, Heath V, Cicero S.
Prenat Diagn 2002;22:308-15. -
One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation.
Nicolaides KH, Bindra R, Heath V, Cicero S.
J Matern Fetal Neonatal Med 2002;12:9-18. -
Platelet changes and subsequent development of pre-eclampsia and fetal growth restriction in women with abnormal uterine artery Doppler screening.
Missfelder-Lobos H, Teran E, Lees C, Albaiges G, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;19:443-8. -
Fetal nasal bone length in chromosomally normal and abnormal fetuses at 11-14 weeks of gestation.
Cicero S, Bindra R, Rembouskos G, Tripsanas C, Nicolaides KH.
J Matern Fetal Neonatal Med 2002;11:400-2. -
Screening for chromosomal defects by fetal nuchal translucency at 11 to 14 weeks.
Bindra R, Heath V, Nicolaides KH.
Clin Obstet Gynecol 2002;45:661-70. -
One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;20:219-25.